On November 30, the European Commission unveiled its proposal for Horizon 2020, the EU’s €79,271 million ($105,713 million = €0.75 = $1) R&D program for 2014 through 2020. The program aims to unite existing EU research programs, simplify and streamline EU funding for R&D, and promote strategic priorities. The program encompasses major EU mechanisms for […]
Two recent announcements by Thermo Fisher Scientific illustrate the company’s commitment to its diagnostics business. Diagnostics is not a new market for the company but, as the news made clear, it is one in which the company has a solid position and one for which it is investing in research. Revenue for Thermo Fisher Scientific’s […]
In what continues to be a busy acquisition period, another set of publicly held analytical instrument companies is set to become one. On September 8, PerkinElmer announced an agreement to acquire Caliper Life Sciences for an estimated $600 million in cash (see page 2). The companies’ complementary product lines and end-markets are a logical combination, […]
Venlo, The Netherlands 6/15/11—QIAGEN announced that it has made an offer and entered into exclusive negotiations to acquire 47% of Ipsogen for €12.90 ($18.60 = €0.69 = $1) per share. Subsequently, QIAGEN would make a public offer to acquire the remainder of the company for the same price, which is a 71.3% premium over Ipsogen’s […]
NanoString Technologies was founded in 2003 to develop a technology to detect and count large sets of target molecules in biological samples. Headquartered in Seattle, Washington, the company employs about 90 people and has raised more than $47 million since it was founded. NanoString Technologies launched its first commercial instrument, the nCounter Analysis System, in […]
Cambridge, MA 5/17/10; Washington, DC 5/17/10—DNA sequencer provider Helicos BioSciences has announced a restructuring plan and strategic shift. The company will now focus solely on molecular diagnostics and has exited the genetic research market. The operational restructuring eliminated 40 positions, or half of the company’s workforce, during the second quarter. “In particular, our technology’s ability […]
Norwalk, CT 2/29/08—Applera has announced its Celera subsidiary, one of the company’s two tracking stocks, along with Applied Biosystems, will pursue a possible spin-off from Applera to become a separately traded public firm (see IBO 8/15/07). Celera provides diagnostic products and services. Holders of the Celera tracking stock would receive Celera shares in a one-for-one […]
Recent acquisitions have highlighted the evolving relationship of instrument companies and the molecular diagnostics market. Last month, QIAGEN acquired Digene, the largest provider of human papillomavirus (HPV) diagnostics tests, for $1.6 billion (see IBO 6/15/07). Earlier this year, Agilent acquired Stratagene for $246.2 million (see IBO 4/15/07). These developments follow acquisitions last year by Luminex […]
Venlo, The Netherlands and Gaithersburg, MD 6/3/07—QIAGEN NV has agreed to acquire publicly listed molecular diagnostics firm Digene for approximately $1.6 billion, including $170 million in cash. QIAGEN will offer Digene stockholders $61.25 in cash per share, a 37% premium over Digene’s June 1 closing price, or 3.545 of QIAGEN stock. QIAGEN and Digene shareholders […]
Pay Invoice
Latest Blogs
-
Lab Instrument Sales in China Collapse
March 29, 2024 1:15 pm
-
Pittcon 2024 Comes to San Diego
February 14, 2024 1:10 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
